Department of Hematology, Medical University of Lodz, Lodz, Poland.
Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland.
Expert Rev Hematol. 2024 Nov;17(11):781-796. doi: 10.1080/17474086.2024.2410003. Epub 2024 Oct 6.
In the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have replaced immunochemotherapy in the treatment of CLL.
This review describes the use of BTK inhibitors and BCL2 inhibitors in the treatment of naive and relapsed or refractory CLL, with particular attention to the mechanisms of resistance. It also addresses the management of double-refractory patients, and the discovery of novel drugs. The corpus of papers was obtained by a search of the PubMed and Google Scholar databases for articles in English.
Covalent BTK inhibitors and venetoclax are commonly recommended for previously-untreated and relapsed/refractory CLL. However, resistance to both drug classes can develop over time. As such, double-refractory patients are difficult to manage and novel approaches are urgently needed.
在过去十年中，BTK 抑制剂和 BCL-2 抑制剂 venetoclax 已取代免疫化疗，用于治疗 CLL。
本文综述了 BTK 抑制剂和 BCL2 抑制剂在初治和复发/难治性 CLL 治疗中的应用，特别关注耐药机制。它还讨论了双重难治患者的管理和新型药物的发现。通过在 PubMed 和 Google Scholar 数据库中搜索英文文献，获得了论文全文。
对于初治和复发/难治性 CLL，通常推荐使用共价 BTK 抑制剂和 venetoclax。然而，随着时间的推移，两种药物类别都可能产生耐药性。因此，双重难治患者难以治疗，迫切需要新的治疗方法。
